
    
      This is a dose-finding study of NKX101 and will be conducted in 2 parts:

      Part 1: dose finding utilizing modified "3+3" enrollment schema.

      Part 2: dose expansion to further evaluate safety and tolerability, cellular kinetics,
      pharmacodynamics and anti-tumor response in expansion cohorts of patients with either AML or
      MDS.
    
  